TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Newly diagnosed MDS patients aged 21 to 65 years belonging to any of the following categories: refractory cytopenia with multilineage dysplasia (RCMD) with or without ringed sideroblasts (i.e. RCMD and RCMD-RS), refractory anemia with excess blasts-1 (RAEB-1) or RAEB-2 if the prognostic scores are IPSS (international prognostic scoring system) Int-2 or IPSS-high or with WPSS (WHO prognostic scoring system) 3 and above~2. Therapy-related MDS with IPSS Int-2 and above or WPSS 3~3. Acceptable cardiac function MUGA or Echocardiography left ventricular ejection fraction of 40% and above~4. Acceptable lung function: FEV1\>70% predicted, DLCO\>60% predicted~5. Acceptable renal function: CCT \> 50ml/min~6. Acceptable liver function: abnormalities in bilirubin or transaminases not \> 2times upper limit of normal~7. Performance status of ECOG 2 or HCT-specific Comorbidity Index \< 3~Exclusion Criteria:~1. Any co-morbidity other than MDS which limits life-expectancy to \<3mth~2. Diagnosis of other active cancer other than squamous cell carcinoma, basal cell carcinoma or carcinoma-in-situ 1 or 2 of the cervix~3. Presence of active infections not under control~4. Receipt of 5-azacytidine or other induction chemotherapy for MDS/AML~5. Patients not keen to explore allogeneic HCT as part of curative treatment plan~6. Pregnancy

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Decitabine 20mg/m\^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Niacin Plus Statin to Prevent Vascular Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 45 and older with established vascular disease and atherogenic dyslipidemia~* Established vascular disease defined as one or more of the following: (1) documented coronary artery disease (CAD); (2) documented cerebrovascular or carotid disease; (3) documented symptomatic peripheral arterial disease (PAD)~* Atherogenic dyslipidemia defined as: (1) LDL-C of less than or equal to 160 mg/dL (4.1 mmol/L); (2) HDL-C of less than or equal to 40 mg/dL (1.0 mmol/L) for men or less than or equal to 50 mg/dL (1.3 mmol/L) for women; (3) TG greater than or equal to 150 mg/dL (1.7 mmol/L) and less than or equal to 400 mg/dL (4.5 mmol/L)~* For patients entering the trial on a statin: (1) the upper limit for LDL-C is adjusted according to the specific statin and statin dose; (2) HDL-C of less than or equal to 42 mg/dL (1.1 mmol/L) for men or less than or equal to 53 mg/dL (1.4 mmol/L) for women; (3) TG greater than or equal to 125 mg/dL (1.4 mmol/L) and less than or equal to 400 mg/DL (4.5 mmol/L)~Exclusion Criteria:~* Coronary artery bypass graft (CABG) surgery within 1 year of planned enrollment (run-in phase)~* Percutaneous coronary intervention (PCI) within 4 weeks of planned enrollment (run-in phase)~* Hospitalization for acute coronary syndrome and discharge within 4 weeks of planned enrollment (run-in phase)~* Fasting glucose greater than 180 mg/dL (10 mmol/L) or hemoglobin A1C greater than 9%~* For patients with diabetes, inability or refusal to use a glucometer for home monitoring of blood glucose~* Concomitant use of drugs with a high probability of increasing the risk for hepatotoxicity or myopathy, such as those predominantly metabolized by cytochrome P450 system 3A4, including but not limited to cyclosporine, gemfibrozil, fenofibrate, itraconazole, ketoconazole, HIV protease inhibitors, nefazodone, verapamil, amiodarone; lipid-lowering drugs (other than the investigational drugs) such as statins, bile-acid sequestrants, cholesterol absorption inhibitors (e.g., ezetimibe), fibrates or high-dose, antioxidant vitamins (vitamins C, E, or beta carotene) that can interfere with the HDL-raising effect of niacin

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination Therapy (Type: EXPERIMENTAL): Extended release niacin plus simvastatin
- Monotherapy (Type: ACTIVE_COMPARATOR): Simvastatin alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: AuraGain and iGel Crossover Comparison

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients who have read and understood patient information leaflets about the study and undergo informed consent.~* patients whose anaesthesia management is being carried out by one of the named investigators~* adult (age \>18 years) patients undergoing general anaesthesia~* American Society of Anaesthesiology Grading (ASA) 1-3~* suitability for general anaesthesia using a laryngeal mask airway device~Exclusion Criteria;~* the presence of significant acute or chronic lung disease~* pathology of neck or upper respiratory tract~* an identified or anticipated difficult intubation~* an increased risk of aspiration (hiatus hernia, gastro-oesophageal reflux or full stomach etc.) pregnant women~* a body mass index greater than 35kg.m-2~* patients unable to communicate fully in English.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- i-Gel and AuraGain (Type: ACTIVE_COMPARATOR): In this arm of the crossover study, patients will undergo insertion of Ambu AuraGain laryngeal mask airway and iGel and will undergo initial management with the iGel. Primary and Secondary outcomes will be assessed. The initial device will be removed and subsequent Airway management will then be undertaken with the Ambu AuraGain and the same outcomes will be assessed.~Interventions with both devices will be~1. Insertion of the laryngeal mask airway~2. Assessment of ease of insertion~3. Ability to perform positive pressure ventilation~4. Measurement of OLP~5. Fibreoptic assessment with Ambu A-scope~6. Ability to insert nasogastric tube~7. Record number of manipulations~8. An assessment of device related trauma
- AuraGain and i-Gel (Type: ACTIVE_COMPARATOR): In this arm of the crossover study, patients will undergo insertion of the Ambu AuraGain laryngeal mask airway and i-Gel and will undergo initial management with the Ambu AuraGain.. Primary and Secondary outcomes will be assessed. Airway management will then be undertaken with the iGel device and the same outcomes will be assessed.~Interventions with both devices will be~1. Insertion of the laryngeal mask airway~2. Assessment of ease of insertion~3. Ability to perform positive pressure ventilation~4. Measurement of OLP~5. Fibreoptic assessment with Ambu A-scope~6. Ability to insert nasogastric tube~7. Record number of manipulations~8. An assessment of device related trauma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria for probable Alzheimer's disease (AD);~* Has a Mini-Mental State Examination total score of 16 to 26;~* Has a Modified Hachinski Ischemia Scale score of ≤ 4;~* Is taking a stable dose of donepezil, galantamine or rivastigmine for at least 30 days;~* Has had a computerized tomography or magnetic resonance imaging. The scan must not show evidence for an alternative etiology for dementia;~* With the exception of a diagnosis of mild-to-moderate AD and the presence of stable medical conditions, is in general good health.~Exclusion Criteria:~* Positive screen for drugs of abuse, alcohol or cotinine;~* Females must not have positive results for pregnancy;~* Focal neurological signs on examination;~* Has a clinically significant abnormal value, in serum chemistry, hematology or urinalysis;~* History of any significant neurologic disease other than AD;~* History of head trauma, motor vehicle accident, concussion.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- ABT-957 (Type: EXPERIMENTAL): ABT-957 administered twice-daily for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered twice-daily for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Receiving adjuvant or neoadjuvant FEC100~Exclusion Criteria:~* Elevated bilirubin~* Abnormal liver or kidney function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Minimally Invasive Tongue Suture For Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Five patients will be recruited during a period of one year, or until a total of five patients have been recruited and have taken part. Patients must have undergone a formal overnight polysomnogram with documented obstructive sleep apnea within the past 2 years with no significant change in their weight or symptoms. They must have tried or refused all available nonsurgical options (CPAP or mandibular advancement devices), and must be ideal candidates for traditional upper airway surgery. Based on the polysomnogram results and specific entry criteria, patients will be recruited. All patients will undergo a full ENT examination and a fiberoptic laryngoscopy, examining the nasal cavity, palatal structures and tongue position, both in the sitting and supine positions (a routine part of the ENT examination).~Entry criteria include the following:~* men and women ages 18 to 65~* supine Park tongue position 3+ or greater~* tonsil size 2 or less~* Mueller's 2+ or less~* Friedman Stage II/III~* BMI ≤ 30~* AHI ≥ 5~Exclusion Criteria:~* Prior pharyngeal surgery~* History of radiation to the head and neck~* Dysmorphic facies or craniofacial syndrome~* ASA class IV or V~* Major depression or unstable psychiatric disorder~* Pregnancy~* Illiteracy (unable to complete required forms)~* No phone # or mailing address, or plans to change in 3 month period~* Any upper airway surgery within three month period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Pilot study of 5 patients, with an additional 20 patients with conditional approval by the IRB once the initial 5 patient's data is reviewed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Asthma (and Dietary) Inflammation Reduction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 10-21 years~* Clinical diagnosis of moderate or severe persistent asthma~* Currently prescribed inhaled corticosteroids for asthma with anticipated stable dosing regimen for the duration of the study~* Admission to Boston Children's Hospital for clinical asthma exacerbation~* Medical clearance from primary care provider~* Willingness to comply with study diet~Exclusion Criteria:~* Body mass index (BMI) \< 3rd centile (age- and gender- adjusted normative range from Center for Disease Control)~* Known eating disorder~* Celiac disease~* Any food allergy~* Any other major illness as assessed by medical history or the following screening tests:~* Alanine aminotransferase (ALT) \> twice upper limit of normal for age~* Creatinine \> 1.0 mg/dL for age 10-18 years; \> 1.2 mg/dL for females \> 18 years; or \> 1.4 mg/dL for males \> 18 years)~* Random glucose \> 200 mg/dL~* Hemoglobin \< 11 g/dL for males age 10-18 years; \< 11. g/dL for females age 10-18 years; \<11.4 g/dL for males \>18 years; or \<10.9 g/dL for females age \> 18 years~* Use of systemic steroids for indication other than asthma

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Anti-Inflammatory Diet First (Type: OTHER): For the first 6 weeks, subjects will receive the anti-inflammatory diet. For the second 6 weeks, subjects will consume their habitual diet.
- Anti-Inflammatory Diet Second (Type: OTHER): For the first 6 weeks, subjects will consume their habitual diet. For the second 6 weeks, subjects will receive the anti-inflammatory diet.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Is 65 to 80 years of age with controlled chronic illness~* agrees to participate in the study by giving written informed consent and cognitively competent as assessed by Mini-Mental State Examination~* for Part I: subject is living independently outside any long-term care facilities; for Part II: subject is expected to be a resident in a long term care facility (LTCF) including nursing homes with the exception of hospice care~* can be adequately followed for safety via visit or phone~* subject's routine safety lab results are within specified ranges~* has negative test results for HIV, Hepatitis B, and Hepatitis C~Exclusion Criteria:~* abdominal cancer/surgery within the past 6 months~* known or suspected immune diseases, e.g. diabetes~* any chronic or relapsing infections~* a fever at the time of immunization~* active vomiting or diarrhea at the time of immunization~* chronic diarrhea, irritable bowel syndrome, or inflammatory disease of intestinal or colon in the past 12 months~* subjects' spouses/cohabitants are not healthy or are immunocompromised; roommates in LTCFs are not healthy and/or do not agree to participate in the study~* cannot be adequately followed for safety via visit or phone~* any other clinically significant conditions that, in the investigators' opinion, would interfere with subject's participation in the study

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Part I, RotaTeq (Type: EXPERIMENTAL): 3 doses of RotaTeq
- Part I, placebo (Type: PLACEBO_COMPARATOR): 3 doses of placebo
- Part II, RotaTeq (Type: EXPERIMENTAL): 3 doses of RotaTeq
- Part II, RotaTeq and placebo (Type: EXPERIMENTAL): 1 dose of RotaTeq and 2 doses of placebo
- Part II, placebo (Type: PLACEBO_COMPARATOR): 3 doses of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Implantation With the Nucleus CI532 Cochlear Implant in Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meet current cochlear implant criteria at the implanting center~* 18 years or older with bilateral sensorineural hearing loss~* Limited benefit from appropriate binaural hearing aids~* Moderate to profound hearing loss in the low frequencies and profound hearing loss in the mid to high frequencies~* Preoperative unaided threshold between 40 and 65 dB HL, inclusively, at 250 Hertz (Hz) and 500 Hz in the ear to be implanted~* Fluent speaker in the language used to assess clinical performance~Exclusion Criteria:~* Evidence of hearing loss prior to age 5~* Sensorineural severe to profound hearing loss greater than 20 years at and above 2000Hz~* Simultaneous bilateral implantation prior to the study~* Medical or psychological conditions that contraindicate undergoing general anesthesia or surgery~* Cochlear anomaly that might prevent complete insertion of the electrode array~* Hearing impairment due to lesion or neuropathy of the acoustic nerve, VIII nerve, or central auditory pathway~* Active middle ear infection~* Tympanic membrane perforation~* Unrealistic expectations~* Unwillingness or inability co comply with all investigational requirements~* Patients with existing cerebral shunts or drains~* Recurrent episodes of bacterial meningitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Surgical (Type: EXPERIMENTAL): Subjects to be implanted with the CI532 cochlear implant in one ear

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Brain Imaging Study of Nicotine Release in Cigarette Smokers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic smokers and healthy non-smokers.~Exclusion Criteria:~* Pregnant and breast feeding women.~* Age below 20.~* Neurological disorders.~* Others drugs.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have received at least one dose of a Juno CAR T-cell product (listed above) in a Juno-sponsored clinical trial~* Patients who have provided informed consent for the long-term follow-up study~Exclusion Criteria:~* None. All patients who have previously received treatment with a Juno CAR T-cell product are eligible for this long-term follow-up study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- JCAR017-treated (Type: None): Patients who received previous treatment with JCAR017
- JCARH125-treated (Type: None): Patients who received previous treatment with JCARH125

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Maraviroc as GVHD Prophylaxis in Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 5 years and \</= 40 years~* All diagnoses~* Peripheral blood stem cells, marrow or cord blood~* All conditioning regimens~* Patient must be planned to receive a calcineurin inhibitor (cyclosporine or tacrolimus) together with steroid, methotrexate or mycophenolate mofetil as GVHD prophylaxis.~Exclusion Criteria:~* Documented anaphylaxis to Maraviroc~* Ex vivo T-cell (type of white blood cell) depleted grafts~* Abnormal Alanine Aminotransferase (ALT) (\>/=10X ULN) on day -3. (Assessed at study enrollment and confirmed again prior to the first dose of maraviroc.)

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Maraviroc (Type: EXPERIMENTAL): Maraviroc administration will start on day -3 and will end on day +30 after stell cell transplant, making the total number of days of drug administration 34 days. Maraviroc will be administered twice daily orally or via enteral tube. Dosing of Maraviroc will be based on body surface area (starting with 100mg twice a day for BSA of 0.2 and up to 300mg twice a day for BSA greater than 1.73).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues